BioPharma Resources

Drug Trial Radar · NCT05616013

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 507 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

507

Actual

Start

Nov 16, 2022

Primary completion

May 16, 2024

Study completion Jun 14, 2025

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
Versanis Bio, Inc.
First posted
Nov 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women

Conditions

  • Obesity
  • Obese
  • Overweight or Obesity

Interventions

  • BimagrumabBiological

    Human monoclonal antibody to the activin receptor type II

  • SemaglutideDrug

    Glucagon-like peptide-1 (GLP-1) receptor agonist

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Body Weight at Week 48Time frame: Baseline, Week 48

Locations

26 sites in 3 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group, LLC

    Anniston, Alabama

  • Cullman Clinical Trials

    Cullman, Alabama

  • Indago Research & Health Center, Inc

    Hialeah, Florida

  • Clinical Neuroscience Solutions Inc

    Jacksonville, Florida

  • Altus Research

    Lake Worth, Florida

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana

  • Weill Cornell Medical College

    New York, New York

  • Monroe Biomedical Research

    Monroe, North Carolina

  • SPICA Clinical

    Columbia, South Carolina

  • Mt. Olympus Medical Research

    Sugar Land, Texas

  • Emeritus Research

    Camberwell, Australia

  • Northern Beaches Clinical Research

    Brookvale, New South Wales, Australia

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • University of The Sunshine Coast Morayfield

    Morayfield, Queensland, Australia

  • University of the Sunshine Coast Clinical Trial Centre

    Sippy Downs, Queensland, Australia

  • University of The Sunshine Coast South Brisbane

    South Brisbane, Queensland, Australia

  • Gold Coast University Hospital

    Southport, Queensland, Australia

  • Austin Health

    Heidelberg Heights, Victoria, Australia

  • New Zealand Clinical Research Auckland

    Auckland, New Zealand

  • Optimal Clinical Trials

    Auckland, New Zealand

  • Middlemore Hospital

    Auckland, New Zealand

  • New Zealand Clinical Research Christchurch

    Christchurch, New Zealand

  • Lakeland Clinical Trials Waikato

    Hamilton, New Zealand

  • Southern Clinical Trials Tasman

    Nelson, New Zealand

  • Southern Clinical Trials Ltd

    Beckenham, Christchurch, Canterbury, New Zealand

  • P3 Research

    Newtown, Wellington Region, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.